RadNet Acquires Gleamer: The Radiology AI Platform Consolidation Thesis Takes Shape

This is an excerpt of Marketstrat’s full strategic analysis. The complete research note — including detailed competitive landscape analysis, integration risk assessment, and company profiles — is available to clients.

EXECUTIVE SUMMARY

On March 2, 2026, RadNet, Inc. (NASDAQ: RDNT) completed its acquisition of Gleamer SAS, a Paris-based radiology AI company, for up to €230 million all-cash. The deal integrates Gleamer into DeepHealth, creating what the combined entity claims is the world’s largest provider of radiology clinical AI solutions: 2,700+ customer contracts across 50+ countries, 26 FDA clearances, 22 CE marks, 75+ clinical indications, and a combined ARR target approaching $140 million by year-end 2026.

The strategic signal matters more than the arithmetic. This acquisition marks a decisive shift in how the radiology AI market is being contested — away from single-indication point solutions and toward vertically integrated workflow platforms.

Marketstrat’s four headline assessments:

This deal closes the most critical gap in DeepHealth’s portfolio — routine imaging. Pre-deal, DeepHealth had no meaningful X-ray AI capability. X-ray represents roughly 25% of RadNet’s own imaging volume. Gleamer’s BoneView, ChestView, and BoneMetrics fill that whitespace immediately, with FDA clearances already in hand.

The strategic logic favors volume economics over clinical acuity. The radiology AI narrative has been dominated by acute-care detection — stroke, PE, aortic dissection. This deal signals a different thesis: that the larger commercial opportunity lies in automating high-volume routine workflows where AI compresses radiologist reading time across millions of exams.

Automated draft reporting is the capability that ties the portfolio together. Gleamer already deploys reporting AI in European clinical settings. Bringing that capability into the U.S. market positions the combined entity to move beyond detection and into report generation — a step-change in the AI value proposition.

The deal accelerates market consolidation that will compress competitive space. Point-solution vendors with narrow portfolios now face an existential question: build, partner, or be acquired.

THE PORTFOLIO STORY

The most immediate rationale is portfolio completion. Exhibit 1 maps the combined portfolio across modalities and clinical areas. The strategic logic is self-evident: the entire X-ray column — blank pre-deal — is now fully populated. The automated draft reporting row lights up entirely through Gleamer’s contribution.

Pre-deal, DeepHealth had assembled clinical AI capabilities in mammography (iCAD, Kheiron), MRI (prostate, neuro), CT (chest, lung), and ultrasound (See-Mode) through six acquisitions since 2020. What it conspicuously lacked was any meaningful X-ray presence — the single highest-volume imaging modality in clinical practice.

Gleamer fills that gap with BoneView (MSK X-ray, K222176), ChestView (thoracic X-ray, K241620), BoneMetrics (fracture measurement, K241593), and BoneAge (pediatric bone maturity). Beyond X-ray, Gleamer adds depth in CT (BoneCT, LungCT), mammography (BreastView), and neuro MRI (Pixyl.Neuro, K213253).

The portfolio is now genuinely comprehensive across all five core imaging modalities. Two gaps remain — cardiac imaging and interventional guidance — but neither is surprising. The critical observation is that DeepHealth now covers the modalities accounting for the vast majority of outpatient radiology volume.

THREE MARKET SIGNALS

Signal 1: Multi-Modality Platform Breadth Is Becoming Table Stakes
Signal 2: Routine Imaging AI Is the Next Frontier
Signal 3: Automated Reporting Is the Endgame

LOOKING AHEAD

RadNet has scheduled a dedicated investor call for March 5, 2026. Key questions include the technology integration architecture (single platform or federated model), productivity metrics for the Q3 2026 internal deployment, and the regulatory strategy for bringing Gleamer’s automated reporting capabilities to U.S. clinical settings.

Sources: RadNet press release (March 2, 2026); RadNet Form 8-K; RadNet Q4/FY2025 earnings release; Gleamer.ai; FDA 510(k) database; DeepHealth.com; Marketstrat competitive intelligence database.

Disclosures: Marketstrat has no financial position in RadNet, Inc. (RDNT) or any entity discussed in this note. This analysis does not constitute investment advice.

About Marketstrat

Marketstrat® is a market intelligence and GTM enablement firm focused on medtech, healthcare, and life sciences. Under the Markintel™ brand, Marketstrat delivers robust market intelligence and proprietary frameworks; through GrowthEngine advisory and tools, it helps clients turn insights into execution. Together, these capabilities support clients in converting evidence‑weighted insight into practical action across strategy, product, and commercial execution.

Marketstrat® and Markintel™ are trademarks of Marketstrat Inc. All other trademarks are the property of their respective owners.

Check out free Research and Insights, Strategic Frameworks & Market Signals and Analysis of Industry Events

Check out our collection of Markintel Horizon and Markintel Pulse research.

Check out details on our reports, World Market for AI in Medical Imaging and World Market for Oncology Imaging AI and other Pulse Reports in the Imaging space.